Do you want to read an article? Please log in or register.
LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial
Lung Cancer
Related content
RECOMMENDED
Asthma
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Allergy Asthma Immunol Res
Chen R, Dai Y, Yang D, Liu C, Han W, Gu W, Cao J, Zhou Q, Howarth P, Weng S, Xiong C, Huang J, Liang P, Zhong N, 201536 Study Group
doi: 10.4168/aair.2025.17.4.473
RECOMMENDED
Lung Cancer
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A
doi: 10.1016/j.lungcan.2024.108059
RECOMMENDED
Asthma
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Patel C, Sheth V, Koppula R, Kumar A, Bhate AS, Sahoo D, Jain MK, Mondal A, Parmar D, Kansagra K, Shrivastava R, Pathak H
doi: 10.1016/j.rmed.2025.108293
RECOMMENDED
Pulmonary Fibrosis
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G
doi: 10.1016/S2213-2600(24)00407-7
RECOMMENDED
COPD
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Christenson SA, Hanania NA, Bhatt SP, Bafadhel M, Rabe KF, Vogelmeier CF, Papi A, Singh D, Laws E, Dakin P, Bansal A, Lu X, Bauer D, Maloney J, Robinson LB, Abdulai RM
doi: 10.1016/S2213-2600(25)00044-X
Lung Cancer
KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort
J Clin Med
Geçgel A, Şahin Çelik B, Peker P, Gökdere ZS, Koca D, Karaca B, Nart D, Göker E
doi: 10.3390/jcm14196826
COMMENTED
COPD
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB
doi: 10.1016/S2213-2600(24)00409-0
RECOMMENDED
Lung Cancer
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A
doi: 10.1016/j.cllc.2025.07.003
RECOMMENDED
Further Publications
Effect of pulmonary rehabilitation for patients with long COVID-19: a systematic review and meta-analysis of randomized controlled trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis
Li S, Dai B, Hou Y, Zhang L, Liu J, Hou H, Song D, Wang S, Li X, Zhao H, Wang W, Kang J, Tan W
doi: 10.1177/17534666251323482